The lead-I electrocardiogram (ECG) devices were assessed when they were used in addition to 12‑lead ECGs. Clinical experts advised that a 12‑lead ECG would still be used after lead-I ECGs to identify ...
DiaCardia, a novel artificial intelligence model that can accurately identify individuals with prediabetes using either 12-lead or single-lead electrocardiogram (ECG) data, has been recently developed ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack ...
Electrocardiograms provide a tested method of diagnosing a variety of cardiac health problems. While some ECG systems are available for home use, no consumer-grade devices can provide the same level ...
DiaCardia, a novel artificial intelligence model that can accurately identify individuals with prediabetes using either ...
LOS ANGELES, CA - June 16, 2025 (NEWMEDIAWIRE) - HeartBeam (NASDAQ: BEAT) announced its synthesized 12-lead ECG met clinical endpoints in the VALID-ECG pivotal study, achieving 93.4% diagnostic ...
Evidence-based recommendations on lead-I electrocardiogram (ECG) devices (imPulse, Kardia Mobile, MyDiagnostick and Zenicor-ECG) for detecting symptomatic atrial fibrillation using single time point ...
HeartBeam has received FDA clearance for its synthesized 12-lead ECG software, making it the first cable-free device of its kind for at-home arrhythmia assessment. The clearance followed a successful ...
Unele rezultate au fost ascunse, deoarece pot fi inaccesibile pentru dvs.
Afișați rezultatele inaccesibile